Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin-tazobactam vs ampicillin-sulbactam for SSI prevention after pancreaticoduodenectomy
jRCTs051260063Recruiting
- Start
- Jul 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in surgical site infection (SSI) comparing Piperacillin-tazobactam arm with Ampicillin-sulbactam arm (2 arms). Primary endpoint: Incidence of surgical site infection within 30 days. Started Jul 2026; status: recruiting.
02
Drugs
piperacillin + tazobactamampicillin + sulbactam
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on jRCTs051260063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260063.